Ameriprise
CELGZ

Ameriprise’s Celgene Corporation Contingent Value Rights CELGZ Stock Holding History

Ameriprise’s Portfolio CELGZ Stock Details CELGZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-1,760
Closed -$6K – 5239
2014
Q3 		$6K Hold
1,760
– – ﹤0.01% 5102
2014
Q2 		$5K Hold
1,760
– – ﹤0.01% 4984
2014
Q1 		$5K Hold
1,760
– – ﹤0.01% 4812
2013
Q4 		$5K Hold
1,760
– – ﹤0.01% 4647
2013
Q3 		$14K Hold
1,760
– – ﹤0.01% 4687
2013
Q2 		$13K Buy
+1,760
New +$12.8K ﹤0.01% 4625

Other funds holding CELGZ

OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
FA
FCG Advisors Chatham, New Jersey $425M AUM 12.09% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Ameriprise's CELGZ Position: Q4 2014 in Review

Ameriprise sold out of Celgene Corporation Contingent Value Rights (CELGZ) in Q4 2014, closing a stake of 1,760 shares — an estimated $6K sold.

Ameriprise first reported a position in CELGZ in Q2 2013 and held it in 6 quarters. The position peaked at $14K in Q3 2013. 23 funds tracked by Wall St. Rank hold CELGZ as of Q4 2014.

  • Ameriprise reported no remaining Celgene Corporation Contingent Value Rights position as of Q4 2014 after selling out during the quarter.
  • Ameriprise sold 1,760 Celgene Corporation Contingent Value Rights shares in Q4 2014, an estimated $6K.
  • Ameriprise first reported a position in Celgene Corporation Contingent Value Rights in Q2 2013 and held it in 6 quarters.
  • Ameriprise's Celgene Corporation Contingent Value Rights position peaked at $14K in Q3 2013.
  • 23 funds tracked by Wall St. Rank held Celgene Corporation Contingent Value Rights as of Q4 2014.

Based on Ameriprise's 13F filing for Q4 2014, filed 13 Feb 2015.